Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. - Wikidata - wikimedia - TriplyDB

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

http://www.wikidata.org/entity/Q42554303

about

PD-L1 expression in human cancers and its association with clinical outcomes Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Immunotherapy advances for glioblastoma The role of regulatory T cells in cancer immunology An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Immune Checkpoint in Glioblastoma: Promising and Challenging Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Increased numbers of Foxp3-positive regulatory T cells in gastritis, peptic ulcer and gastric adenocarcinoma.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Differential correlation analysis of glioblastoma reveals immune ceRNA interactions predictive of patient survival CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.PD-1 marks dysfunctional regulatory T cells in malignant gliomas.Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.Immunocombination therapy for high-risk neuroblastoma.Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Clinical trials in cellular immunotherapy for brain/CNS tumors.Vaccine therapies for patients with glioblastoma.Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme.Immunotherapeutic advancements for glioblastoma.Immune Checkpoint Inhibitors in Gliomas.Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.Advances in immunotherapy for the treatment of glioblastoma.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients Cytotoxic CD4+ T cells are correlated with better prognosis in Han Chinese grade II and grade III glioma subjects and are suppressed by PD-1 signaling.Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.The role of STAT3 activation in modulating the immune microenvironment of GBM.Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.

P2860

Q26738361-C59831EA-0ED8-4C4A-996B-324CF9DB9468 Q26765459-EDE921EF-EEB7-4063-B87D-0D12ADADF08A Q26866513-E778BA8F-D7CD-40C9-A833-7C457ED53E7D Q27006663-4B6F70EC-FA90-4FF8-8E78-AA9ADD689FEB Q27024830-EE9AF036-0B13-427F-AA9E-333C1618943F Q30578330-3BFE2BE3-C82E-4FB2-B2D2-ABB0D4BC9263 Q33650058-C070CDF8-CCF8-4832-B0AB-BF49CB42C0F3 Q34129168-AB4BF469-13C8-467A-A69D-2B684A1B0E93 Q34315871-504153E6-A517-4B58-9F82-93A1846AFEE1 Q34744875-49B11974-55F4-448E-AC9C-4B7C4F5E60D7 Q35060537-1D48FC2B-351D-4B61-BC88-649D9DF984B8 Q35142813-EFF8B197-34DD-4ED1-BADA-ECBDCB419DBB Q35553553-1521E8E0-BD68-414F-AE4E-B37808A9CEFC Q35653584-CAB69AA7-3D51-4267-9CD2-D5F102B10887 Q36086507-F082636A-7FCD-44E9-9940-84625ACC2B26 Q36292015-C6C8DB2A-8678-4BF2-8750-BCDD06DE60A4 Q36893225-A4DDF3BB-96A7-42C8-87F1-9C2A212FD5A6 Q36895616-E6A492DC-7953-4FE3-9DF8-733A50955DDD Q37952245-7C45B95F-1E0B-417F-A9AA-9601C21473E2 Q37970682-BFB8EFA6-7F1C-4E45-834F-4035359E1218 Q37991024-23AA1D83-EE23-49EF-A153-5D69031B6707 Q37991701-47608572-FF09-45C0-A905-6BDF371606D5 Q38094811-A789100C-9864-41D5-9A52-A1C019007C3A Q38243975-4526AF13-D390-4F21-B51C-ECBBD895A18A Q38262132-4FC4F179-8331-45E4-943F-5A629C9E6B62 Q38358124-C4DBF7E0-6D00-48EF-976A-F5299F6009E6 Q38743793-6A1CD0D0-ABBA-4794-89FB-3583B1B67448 Q38907925-57DA6E8E-995F-4C1B-8047-785488A19B1A Q38981383-D282EF58-CAC9-4F33-9AA5-3E38533ED0B5 Q38987239-B6D93765-6246-4A76-A57B-CA55428A6B73 Q39004582-185E3E0C-8D28-4410-A938-113444F05509 Q39479166-9B635DEC-D774-4253-8615-326635F37367 Q39775953-DD181393-CF1D-44A8-A569-157DE68FDBF6 Q39838078-37A06FAE-BA7D-47FF-A432-63700C9F1284 Q39896275-536AA760-42B5-431C-9A45-FE4085026F6A Q40082730-0E99B1CD-54F7-41AD-A068-1C7893CEC21D Q41101153-76A202E6-8036-4241-BE79-55451242B09A Q41876866-42E90CE0-C1E4-4D5C-9B18-BAA43436E9AD Q42057288-DE03E003-D6B1-44AD-84D7-7E6C9D337246 Q42927241-B6E45FF9-7554-42E8-B46C-68E90A9F7CCE

P2860

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

http://www.wikidata.org/entity/Q42554303

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Regulatory T cells and the PD- ...... malignant human brain tumors.

@en

Regulatory T cells and the PD- ...... malignant human brain tumors.

@nl

type

label

Regulatory T cells and the PD- ...... malignant human brain tumors.

@en

Regulatory T cells and the PD- ...... malignant human brain tumors.

@nl

prefLabel

Regulatory T cells and the PD- ...... malignant human brain tumors.

@en

Regulatory T cells and the PD- ...... malignant human brain tumors.

@nl

P1433

Q42554303-2BE69943-7204-439A-A5D7-3C37E4ADD8A4

P1476

Q42554303-23FB599E-30B0-4123-91F8-4315CF7A60CD

P2093

Q42554303-0BB9F2BB-F96B-4597-8254-565873EDF1A7

Q42554303-0E4A1859-A31E-42D2-9D2B-181B61C995FA

Q42554303-1C522A45-10FA-4FB5-964C-535BEEDA0024

Q42554303-1DC75A0F-BD9C-41DC-BB2B-EDF6486C0E84

Q42554303-3726F501-66A5-435B-8913-395C7540AB63

Q42554303-61AEE9E0-FDAD-4BE3-AD26-0287859638E4

Q42554303-761BDE05-2E00-49EA-8118-0019DFAC2524

P2860

Q42554303-083D1438-27EF-4FD4-92B8-2C7F2C5C7E60

Q42554303-0FF8AC6B-1142-43EB-8AA9-5AD5D6D8BF4A

Q42554303-155EEEC5-0AC7-4321-BD64-807324A8121F

Q42554303-19514B97-2DAA-4F97-8C4C-1156FFBF237F

Q42554303-1C79A23F-80E6-4524-9F9E-B6C6002426B5

Q42554303-20B9B4A5-F54C-4540-B938-5A2FAA67035B

Q42554303-2595935E-9CEE-4A8C-9874-ABFB2115CDC0

Q42554303-2A8E3DC5-580D-4AEE-9582-B1FD361AE500

Q42554303-34B7D21C-2210-45AA-8C2C-06B1AB204436

Q42554303-3561B089-43AE-4AA8-86CB-4C0D7A2A141B

P304

Q42554303-CE364AD5-5F36-4372-99D3-18FA6D659336

P31

Q42554303-941203D0-D038-4FA7-8712-F64FD0E8413A

P356

Q42554303-E79CF6B7-65B0-458B-B56B-E6284B06F531

P433

Q42554303-1FF20B9B-D3BF-4589-9B9B-E53865AA407F

P478

Q42554303-F7F90BD2-F6A1-441A-9559-021FD28BA26D

P50

Q42554303-1CB03CC9-AF1B-4738-ADD4-493EFFAF3E29

Q42554303-29136C7F-2641-4E91-97FB-302182082F80

Q42554303-29478BFF-6E89-4154-AB13-F9341E995E2C

P577

Q42554303-5FDF329C-713E-41B5-89F4-2DE47DF8C5C7

P5875

Q42554303-320A61C6-2776-4A0A-9751-4263D3BE8AA6

P698

Q42554303-96B697A9-6543-4057-B4B5-7DE757AD46E2

P932

Q42554303-C795E979-FF5F-45A3-9B35-8E00C36B2430

P356

15228517-2008-104

P1433

P1476

Regulatory T cells and the PD- ...... n malignant human brain tumors

@en

P2093

Albert J Idema

http://www.w3.org/2001/XMLSchema#string

Gosse J Adema

http://www.w3.org/2001/XMLSchema#string

I Jolanda M de Vries

http://www.w3.org/2001/XMLSchema#string

J André Grotenhuis

http://www.w3.org/2001/XMLSchema#string

Oliver M Grauer

http://www.w3.org/2001/XMLSchema#string

Peter M Hoogerbrugge

http://www.w3.org/2001/XMLSchema#string

Pieter Wesseling

http://www.w3.org/2001/XMLSchema#string

P2860

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

Toll-like receptor 2 controls expansion and function of regulatory T cells

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells.

P304

394-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/15228517-2008-104

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Stefan Nierkens

Joannes F. M. Jacobs

P577

2008-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23492898

http://www.w3.org/2001/XMLSchema#string

P698

19028999

http://www.w3.org/2001/XMLSchema#string

P932

2743219

http://www.w3.org/2001/XMLSchema#string